Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has been given a consensus recommendation of "Buy" by the eight analysts that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $22.00.
Several analysts have recently weighed in on the stock. HC Wainwright raised shares of Aura Biosciences to a "buy" rating and set a $22.00 price objective for the company in a report on Wednesday, May 28th. JMP Securities reaffirmed a "market outperform" rating and set a $19.00 price objective on shares of Aura Biosciences in a report on Friday, May 23rd. Finally, Citigroup reaffirmed an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th.
Read Our Latest Research Report on AURA
Insider Activity at Aura Biosciences
In related news, insider Anthony S. Gibney purchased 50,000 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was acquired at an average price of $4.90 per share, with a total value of $245,000.00. Following the completion of the acquisition, the insider now directly owns 58,452 shares in the company, valued at approximately $286,414.80. This trade represents a 591.58% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Michael Johnson purchased 20,000 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was bought at an average cost of $4.90 per share, with a total value of $98,000.00. Following the acquisition, the director now owns 166,167 shares of the company's stock, valued at $814,218.30. This represents a 13.68% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 9,578 shares of company stock valued at $52,067 over the last quarter. Corporate insiders own 5.40% of the company's stock.
Institutional Trading of Aura Biosciences
Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE grew its holdings in Aura Biosciences by 20.5% during the 4th quarter. Bank of America Corp DE now owns 51,286 shares of the company's stock worth $422,000 after acquiring an additional 8,709 shares during the period. Geode Capital Management LLC grew its holdings in Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock worth $8,327,000 after acquiring an additional 3,972 shares during the period. Wellington Management Group LLP grew its holdings in Aura Biosciences by 12.6% during the 4th quarter. Wellington Management Group LLP now owns 131,054 shares of the company's stock worth $1,077,000 after acquiring an additional 14,662 shares during the period. ProShare Advisors LLC acquired a new stake in Aura Biosciences during the 4th quarter worth $127,000. Finally, Deutsche Bank AG grew its holdings in Aura Biosciences by 56.7% during the 4th quarter. Deutsche Bank AG now owns 44,085 shares of the company's stock worth $362,000 after acquiring an additional 15,951 shares during the period. Institutional investors and hedge funds own 96.75% of the company's stock.
Aura Biosciences Trading Down 0.2%
NASDAQ:AURA traded down $0.01 during mid-day trading on Wednesday, hitting $6.28. The company's stock had a trading volume of 1,310,379 shares, compared to its average volume of 210,219. Aura Biosciences has a fifty-two week low of $4.35 and a fifty-two week high of $12.38. The company has a market capitalization of $315.70 million, a price-to-earnings ratio of -3.31 and a beta of 0.42. The stock has a fifty day moving average of $5.95 and a 200-day moving average of $6.85.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.08). On average, equities analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.
About Aura Biosciences
(
Get Free ReportAura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Stories
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
